HC Wainwright Issues Negative Forecast for CGEM Earnings

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – HC Wainwright dropped their Q1 2027 earnings estimates for Cullinan Therapeutics in a research note issued to investors on Friday, September 25th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.95) per share for the quarter, down from their prior estimate of ($0.77). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q2 2027 earnings at ($0.96) EPS, Q3 2027 earnings at ($0.98) EPS, Q4 2027 earnings at ($1.00) EPS and FY2027 earnings at ($3.89) EPS.

A number of other research firms have also issued reports on CGEM. BTIG Research reiterated a “buy” rating and set a $40.00 target price on shares of Cullinan Therapeutics in a report on Friday, September 25th. Wedbush lifted their price objective on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Wall Street Zen downgraded shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. Finally, TD Cowen upgraded shares of Cullinan Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cullinan Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.71.

Cullinan Therapeutics Stock Up 1.9%

CGEM stock opened at $15.23 on Tuesday. The company has a market cap of $980.20 million, a price-to-earnings ratio of -4.91 and a beta of 0.02. The business has a fifty day simple moving average of $19.66 and a 200-day simple moving average of $16.71. Cullinan Therapeutics has a 52 week low of $5.68 and a 52 week high of $23.19.

Cullinan Therapeutics (NASDAQ:CGEM) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Cullinan Therapeutics in the second quarter worth $95,289,000. Blue Owl Capital Holdings LP acquired a new stake in shares of Cullinan Therapeutics in the 2nd quarter worth about $28,039,000. Boothbay Fund Management LLC acquired a new stake in shares of Cullinan Therapeutics in the 4th quarter worth about $12,803,000. Dimensional Fund Advisors LP lifted its position in Cullinan Therapeutics by 6.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company’s stock valued at $12,870,000 after purchasing an additional 57,259 shares during the last quarter. Finally, Boone Capital Management LLC bought a new stake in Cullinan Therapeutics in the 2nd quarter valued at about $12,828,000. 86.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $21.57, for a total value of $172,560.00. Following the completion of the transaction, the insider owned 158,844 shares of the company’s stock, valued at $3,426,265.08. The trade was a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last ninety days, insiders sold 46,000 shares of company stock valued at $922,920. 8.60% of the stock is currently owned by insiders.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.